Kilian Irlinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kilian Irlinger has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Abirami Augsburger
Department of Medicine III, TUM University Hospital, Technical University of Munich, Munich, Germany
1 shared publicationAndrej Besse
Department of Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
1 shared publication- Angela M. Krackhardt
Medical Department III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany
1 shared publication Anna Purcarea
Department of Medicine III, TUM University Hospital, Technical University of Munich, Munich, Germany
1 shared publicationBernhard Kuster
Deutsches Konsortium für Translationale Krebsforschung, Heidelberg, Germany
1 shared publicationCarolin Vogelsang
Department of Medicine III, TUM University Hospital, Technical University of Munich, Munich, Germany
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 29 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (5) , 534-546
Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens
Chimeric antigen receptor (CAR) T cells exhibit high response rates in B-cell malignancies, but most patients eventually relapse. A key mechanism of treatment failure is the loss or downregulation of tumor antigen expression, yet strategies to modulate cell surface levels of CAR T-cell targets remain largely unexplored. Here, we identify B-cell maturation antigen (BCMA), a central CAR T-cell target in multiple myeloma (MM), as a highly short-lived protein that undergoes K48-linked polyubiquitylation at the plasma membrane, leading to its p97-dependent degradation via the ubiquitin-proteasome system (UPS). This previously unprecedented mechanism of plasma membrane protein regulation enables significant enhancement of BCMA expression via proteasome inhibitors (PIs). The clinically approved PI carfilzomib (CFZ) significantly enhances the efficacy of BCMA-directed CAR T cells against both PI-sensitive and -refractory MM cells in vitro and in vivo. Notably, CFZ treatment of 10 patients with BMCA CAR T-cell therapy relapse, under the CFZ after BCMA CAR T-cell (CarCAR) protocol, resulted in increased BCMA expression in all patients. However, clinical responses were observed only in those with residual and/or expanding CAR T cells, suggesting restored CAR T-cell function. These findings provide a rationale for the use of CFZ treatment in relapsed or refractory MM after BCMA CAR T-cell therapy, advocate for future trials combining CFZ with BCMA CAR T cells, and provide a framework for exploring UPS-dependent degradation of other immunotherapy antigens.
- 29 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (5) , 534-546
Top Cited PapersOpen AccessBoosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens
Chimeric antigen receptor (CAR) T cells exhibit high response rates in B-cell malignancies, but most patients eventually relapse. A key mechanism of treatment failure is the loss or downregulation of tumor antigen expression, yet strategies to modulate cell surface levels of CAR T-cell targets remain largely unexplored. Here, we identify B-cell maturation antigen (BCMA), a central CAR T-cell target in multiple myeloma (MM), as a highly short-lived protein that undergoes K48-linked polyubiquitylation at the plasma membrane, leading to its p97-dependent degradation via the ubiquitin-proteasome system (UPS). This previously unprecedented mechanism of plasma membrane protein regulation enables significant enhancement of BCMA expression via proteasome inhibitors (PIs). The clinically approved PI carfilzomib (CFZ) significantly enhances the efficacy of BCMA-directed CAR T cells against both PI-sensitive and -refractory MM cells in vitro and in vivo. Notably, CFZ treatment of 10 patients with BMCA CAR T-cell therapy relapse, under the CFZ after BCMA CAR T-cell (CarCAR) protocol, resulted in increased BCMA expression in all patients. However, clinical responses were observed only in those with residual and/or expanding CAR T cells, suggesting restored CAR T-cell function. These findings provide a rationale for the use of CFZ treatment in relapsed or refractory MM after BCMA CAR T-cell therapy, advocate for future trials combining CFZ with BCMA CAR T cells, and provide a framework for exploring UPS-dependent degradation of other immunotherapy antigens.